Abbott Laboratories (ABT)vsGlobus Medical (GMED)
ABT
Abbott Laboratories
$103.10
+1.12%
HEALTHCARE · Cap: $176.41B
GMED
Globus Medical
$74.19
+0.86%
HEALTHCARE · Cap: $10.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 1381% more annual revenue ($46.59B vs $3.14B). GMED leads profitability with a 17.0% profit margin vs 11.7%. GMED appears more attractively valued with a PEG of 1.73. GMED earns a higher WallStSmart Score of 60/100 (C+).
ABT
Buy54
out of 100
Grade: C-
GMED
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$74.13
Current Price
$103.09
$28.97 premium
Margin of Safety
+37.2%
Fair Value
$140.62
Current Price
$74.19
$66.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 24.8%
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
Expensive relative to growth rate
Earnings declined 26.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : GMED
The strongest argument for GMED centers on Debt/Equity, Altman Z-Score, Price/Book. Profitability is solid with margins at 17.0% and operating margin at 24.8%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while GMED is a mature play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.96 — expect wider price swings.
ABT is growing revenue faster at 13.0% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (60/100 vs 54/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?